Publications en collaboration avec des chercheurs de Hospital Universitario Araba (18)

2024

  1. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  2. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics

  3. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology

  4. Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study

    International Journal of Colorectal Disease, Vol. 39, Núm. 1

2023

  1. Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease

    United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 9, pp. 1428-1435

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

    Digestive Diseases and Sciences, Vol. 66, Núm. 6, pp. 2014-2023

  2. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

2020

  1. Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)

    Gastroenterology, Vol. 159, Núm. 2, pp. 781-783

  2. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2019

  1. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry

    Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870

2018

  1. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors

    Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819

  2. Methotrexate Pneumonitis in Crohn's Disease: A Rare Case Report and Review of Literature

    Archivos de Bronconeumologia, Vol. 54, Núm. 10, pp. 535-536

2017

  1. Colitis quística profunda: informe de 2 casos con 15 años de seguimiento

    Gastroenterologia y Hepatologia, Vol. 40, Núm. 6, pp. 406-408

2013

  1. Effectiveness of infliximab in the treatment of perianal fistulas in ulcerative colitis: Report of two cases

    Annals of Gastroenterology, Vol. 26, Núm. 3, pp. 261-263

  2. Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab

    World Journal of Gastroenterology, Vol. 19, Núm. 4, pp. 590-593